189818-65-3

Upstream product

• 111878-21-8 2-trimethylsilyloxy-4-trimethylsilylamino-5-fluoropyrimidine 
• 189818-64-2 1-O-acetyl-5-O-(tert-butyldiphenylsilyl)-3-deoxy-2-Se-phenyl-2-seleno-α-and-β-L-erythro-pentofuranose 
• 190078-48-9 (3R,5R)-5-(tert-Butyl-diphenyl-silanyloxymethyl)-3-phenylselanyl-dihydro-furan-2-one 
• 189818-62-0 5-O-(tert-butyldiphenylsilyl)-3-deoxy-2-Se-phenyl-2-seleno-L-erythro-pentonic acid-γ-lactone 
• 34837-55-3 Phenylselenyl bromide 
• 71098-88-9 N-phenylselanylphthalimide 

Downstream Products

• 181785-84-2 elvucitabine 
• 147058-39-7 1-(2,3-dideoxy-beta-L-ribofuranosyl)-5-fluorocytosine 
• 189818-66-4 4-Amino-1-[(2S,5R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-2,5-dihydro-furan-2-yl]-5-fluoro-1H-pyrimidin-2-one 
• 189818-67-5 4-Amino-1-[(2S,5R)-5-(tert-butyl-diphenyl-silanyloxymethyl)-tetrahydro-furan-2-yl]-5-fluoro-1H-pyrimidin-2-one 

Relevant academic research and scientific papers

Stereoselective syntheses of β-L-FD4C and β-L-FddC

Stereocontrolled syntheses of two potent antiviral agents, β-L-FD4C and β-L-FddC, were accomplished both in 10-step sequences, with an overall yield of 27% and 25%, respectively. It is worthwhile to mention that the introduction of a phenylseleno moiety to the C-2α position of the lactone 4 can now be performed in a stereocontrolled fashion, providing the key intermediate 5α in 75% yield.